Publications for Roopali Sharma roopali.sharma2@touro.edu

Moy, S., & Sharma, R. (2017). Treatment outcomes in infections caused by "SPICE" (Serratia, Pseudomonas, indole-positive Proteus, Citrobacter, and Enterobacter) organisms: Carbapenem versus noncarbapenem Regimens. Clinical Therapeutics, 39(1), 170-176. doi:10.1016/j.clinthera.2016.11.025

Banniettis, N., Sharma, R., Hand, I., Peloquin, C. A., Kohlhoff, S., & Hammerschlag, M. R. (2016). Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis. Journal of Antimicrobial Chemotherapy, 71(6), 1738-1739. doi:10.1093/jac/dkv507

Park, T. E., Yusuff, J., Sharma, R. (2016). Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. International Journal of STD & AIDS, 27(6), 447-452. doi:10.1177/0956462415585448

Sharma, R., Park, T. E., & Moy, S. (2016). Ceftazidime-avibactam: A novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant gram-negative organisms. Clinical Therapeutics, 38(3), 431-444. doi:10.1016/j.clinthera.2016.01.018

Swamy, S., & Sharma, R. (2016). Duration of treatment of gram-negative bacteremia: Are shorter courses of antimicrobial therapy feasible? Infectious Diseases in Clinical Practice, 24(3), 155-160. doi:10.1097/IPC.0000000000000362

Moy, S., & Sharma, R. (2015). Treatment outcomes for infections caused by "SPICE" (S–Serratia, P–Pseudomonas aeruginosa, I–Indole positive Proteus, C–Citrobacter, E–Enterobacter) organisms: Carbapenem versus non-carbapenem regimens. Open Forum Infectious Diseases, 2(Suppl. 1), S241. This material can be found here.

Park, T. E., Mohamed, A., Kalabalik, J., & Sharma, R. (2015). Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Review of Anti-Infective Therapy, 13(10), 1195-1212. doi:10.1586/14787210.2015.1075393